News Column

ADVANCED CELL TECHNOLOGY, INC. FILES (8-K) Disclosing Change in Directors or Principal Officers

August 6, 2014

Item 5.02 Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the previously announced appointment of Paul K. Wotton as Chief Executive Officer and President of Advanced Cell Technology, Inc. (the "Company"), the Board of Directors (the "Board") of the Company appointed Dr. Wotton to serve as a director, effective July 31, 2014, until the next annual meeting of the Company's stockholders, where he will stand for election. The appointment of Dr. Wotton as a director brings the size of the Company's Board to six members.

At the time of this disclosure, Dr. Wotton was named to the pricing committee of the Board; no other committee assignments are contemplated at this time. There are no family relationships between Dr. Wotton and any director or executive officer of the Company. Other than as provided in the employment agreement between the Company and Dr. Wotton dated as of June 18, 2014 filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on June 24, 2014, Dr. Wotton has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Edgar Glimpses

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters